Spinnovation announces that it further anchors its presence in the US market through the collaboration with Quantum Tessera in Collegeville, Pennsylvania. This exciting extension to the business came after the Company trebled the number of clients in the biotech and pharma markets last year. Internationally renowned specialist in the field of biologics, Dr Edward Zartler from Quantum Tessera, will be working with Spinnovation to develop biologic and biosimilar characterisation markets in the US.

Spinnovation's Spedia-NMR^TM technology provides detailed, rapid, cost-effective quantitative multiplex analysis of cell culture media. It allows clearly defined data to be revealed on over 50 compounds that may not have been analysed before, and so supports businesses in upscaling upstream development prior to the production of new biologics. This move illustrates that Spinnovation's expertise in spent media analysis and bioprocess troubleshooting, will be utilised when implementing new projects in US markets.

Dr Frederic Girard, CEO of NMR services specialist Spinnovation said "The new presence in the US has enabled us to take advantage of the expanding interest in bioprocess technologies to support the manufacture of biologics. We are gaining momentum with new companies in new markets, and are very excited to see what the future holds."

Dr. Teddy Zartler, Quantum Tessera President and CSO said "I am excited to be able to bring Spinnovation's technologies to the US markets. This will provide a range of services currently not available that will prove to be immediately impactful."

The Spinnovation team will be collaborating with Dr. Edward Zartler to develop the bioprocess and biologics markets to bring together innovative methods for new and existing  clients.

For further information, please visit: www.spinnovation-biologics.com